Compare NPKI & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | WGS |
|---|---|---|
| Founded | 1932 | 2017 |
| Country | United States | United States |
| Employees | 510 | 1300 |
| Industry | Metal Fabrications | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | NPKI | WGS |
|---|---|---|
| Price | $14.27 | $67.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $14.17 | ★ $120.71 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.39 | $29.98 |
| Revenue Next Year | $11.70 | $25.92 |
| P/E Ratio | ★ $38.65 | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.17 | $32.21 |
| 52 Week High | $16.50 | $170.87 |
| Indicator | NPKI | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 60.20 |
| Support Level | $13.70 | $55.76 |
| Resistance Level | $15.28 | $73.46 |
| Average True Range (ATR) | 0.77 | 4.44 |
| MACD | -0.06 | 0.99 |
| Stochastic Oscillator | 13.16 | 69.99 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom. It generates maximum revenue from United States.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.